Mark P. De Souza
Advisor
biotechnology
Adagene
China
Biography
Mark P. de Souza, PhD is a serial entrepreneur, investor, and biotechnology consultant based in the San Francisco Bay area. He is passionate about developing first-in-class therapies for rare and neglected diseases with a high unmet medical need. He is a co-founder and member of the board of directors of NFlection Therapeutics , Myotherix, and ChromaDerm. He is a board member of Excelimmune. Mark was formerly President and CEO of Lotus Tissue Repair and a member of its board of directors. Mark co-founded Lotus Tissue Repair in 2010 to develop recombinant collagen VII as protein replacement therapy for a devastating orphan genetic disease, dystrophic epidermolysis bullosa. Lotus Tissue Repair secured a $26 million Series A commitment from Third Rock Ventures in 2011. The company was acquired by Shire in early 2013.
Research Interest
biotechnology
